Therapeutic Potential of a Novel Polyherbal Formulation: Assessments in Exogenous and Endogenous Dyslipidemia Models | Chapter 9| Current Progress in Medicine and Medical Research Vol. 5

 This episode was designed to judge the effects of a novel herbal cure called “GANMO” on experimental subject models. Dyslipidemia refers to the excess rank of fatty substances containing cholesterol, triglyceride, low-mass lipoprotein (LDL-C), and decreased extreme-density lipoprotein cholesterol (HDL-C) in the bloodstream. In this study, we secondhand Propylthiouracil (Rieserstat®)50mg, Cholesterol (Merk-Germany), Acid Cholic, Poloxamer 407, (Sigma–Singapore), Atorvastatin 10mg (Stellapharm J.V. Co., Ltd), Peanut oil (Vietnam). Our finding accompanied that TG concentration raised substantially by 6.8-fold, TC levels and non-HDL-C concentrations raised by 2.9-fold and 4.1-fold respectively. Base on the success of the P-407 inferred hyperlipidemia model, the effects of the GANMO capsule could be judged precisely. GANMO significantly discounted serum total cholesterol (TC) and non-extreme-density lipoprotein cholesterol (non-HDL-C) levels in two together models at both doses when compared to the model group. Rats likely high doses of GANMO had greater levels of HDL cholesterol than rats given reduced doses.  GANMO at both doses diminished substantially TG level in the endogenous hyperlipidemia model. In conclusion, GANMO tablets formal a positive effect on antitoxin lipid modulations in dyslipidemia models.

Author(s) Details:

Pham Ba Tuyen,

Traditional Medicine Hospital, Ministry of Public Security, Hanoi, Vietnsam.

Truong Thi Huyen,

Traditional Medicine Hospital, Ministry of Public Security, Hanoi, Vietnsam.

Dinh Thi Thu Hang,

Hanoi Medical University, Hanoi, Vietnam.

Pham Thi Van Anh,

Hanoi Medical University, Hanoi, Vietnam.

Please see the link here: https://stm.bookpi.org/CPMMR-V5/article/view/11389